31st Mar 2016 14:00
31 March 2016 |
Skyepharma PLC ("the Company")
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
The Company was informed on 31 March 2016 that, as a result of a transaction on 31 March 2016, Peter Grant, the Company's Chief Executive Officer, transferred 20,000 ordinary shares of 100 pence each ("Ordinary Shares") in the Company to his spouse, for nil consideration.
Following the transfer, Peter Grant and his connected parties continue to have a beneficial interest in 207,366 Ordinary Shares, representing approximately 0.19% of the issued share capital of the Company, being the same as previously notified.
Enquiries:
Antony Taylor, Assistant Company Secretary, Tel. 020 7881 1173
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L